Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CD81 | P60033 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523050 | 1.00 | TSHR (0.42) | TSHRCD81PPARGPTGS1EP300 | |
| SCHEMBL9407669 | 0.89 | CD81 (0.39) | TSHRCD81PPARGPTGS1EP300 | |
| SCHEMBL22528431 | 0.87 | CD81 (0.38) | TSHRCD81PPARGPTGS1BACE1 | |
| SCHEMBL9983159 | 0.82 | TDP1 (0.40) | TSHRCD81PPARGPTGS1BACE1 | |
| SCHEMBL9571096 | 0.82 | CD81 (0.35) | CD81PPARGBACE1 | |
| SCHEMBL28569115 | 0.80 | CD81 (0.37) | CD81PPARGPTGS1 | |
| SCHEMBL20837813 | 0.80 | CES2 (0.50) | PTGS1EP300 | |
| SCHEMBL7649872 | 0.80 | CES2 (0.50) | PTGS1EP300 | |
| SCHEMBL20837814 | 0.80 | CES2 (0.50) | PTGS1EP300 | |
| SCHEMBL1704918 | 0.78 | TDP1 (0.42) | CD81PPARGPTGS1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| EP-1781098-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0933399-B1 | Aminosilicone oil emulsions crosslinked by Michael addition-type reactions | WACKER CHEMIE GMBH (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-0972811-A1 | Radiation curable copolymer compositions | Wacker-Chemie GmbH (DE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0762197-B1 | Photographic recording material | AGFA GEVAERT AG (DE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0933399-A1 | Aminosilicone oil emulsions crosslinked by Michael addition-type reactions | Wacker-Chemie GmbH (DE) | 1999-08-04 | — | — | EP | disclosed |
| EP-0762197-A1 | Photographic recording material | Agfa-Gevaert AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| US-5587279-A | HIGH CONCENTRATION OF SILVER CHLORIDE GRAINS | FUJI PHOTO FILM CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| EP-0666498-A2 | Silver halide photographic material | Agfa-Gevaert AG (DE) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | TSHR 4664/4885CD81 467/4885PPARG 1792/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | TSHR 4664/4885CD81 467/4885PPARG 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.